JP2024502433A5 - - Google Patents

Info

Publication number
JP2024502433A5
JP2024502433A5 JP2023540770A JP2023540770A JP2024502433A5 JP 2024502433 A5 JP2024502433 A5 JP 2024502433A5 JP 2023540770 A JP2023540770 A JP 2023540770A JP 2023540770 A JP2023540770 A JP 2023540770A JP 2024502433 A5 JP2024502433 A5 JP 2024502433A5
Authority
JP
Japan
Application number
JP2023540770A
Other languages
Japanese (ja)
Other versions
JPWO2022147246A5 (https=
JP2024502433A (ja
JP7791196B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/065679 external-priority patent/WO2022147246A1/en
Publication of JP2024502433A publication Critical patent/JP2024502433A/ja
Publication of JP2024502433A5 publication Critical patent/JP2024502433A5/ja
Publication of JPWO2022147246A5 publication Critical patent/JPWO2022147246A5/ja
Priority to JP2025243767A priority Critical patent/JP2026048777A/ja
Application granted granted Critical
Publication of JP7791196B2 publication Critical patent/JP7791196B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023540770A 2020-12-30 2021-12-30 キナーゼ阻害剤としてのインダゾール化合物 Active JP7791196B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025243767A JP2026048777A (ja) 2020-12-30 2025-12-09 キナーゼ阻害剤としてのインダゾール化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063132031P 2020-12-30 2020-12-30
US63/132,031 2020-12-30
US202163216879P 2021-06-30 2021-06-30
US63/216,879 2021-06-30
PCT/US2021/065679 WO2022147246A1 (en) 2020-12-30 2021-12-30 Indazole compounds as kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025243767A Division JP2026048777A (ja) 2020-12-30 2025-12-09 キナーゼ阻害剤としてのインダゾール化合物

Publications (4)

Publication Number Publication Date
JP2024502433A JP2024502433A (ja) 2024-01-19
JP2024502433A5 true JP2024502433A5 (https=) 2025-01-09
JPWO2022147246A5 JPWO2022147246A5 (https=) 2025-01-09
JP7791196B2 JP7791196B2 (ja) 2025-12-23

Family

ID=80168316

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023540770A Active JP7791196B2 (ja) 2020-12-30 2021-12-30 キナーゼ阻害剤としてのインダゾール化合物
JP2025243767A Pending JP2026048777A (ja) 2020-12-30 2025-12-09 キナーゼ阻害剤としてのインダゾール化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025243767A Pending JP2026048777A (ja) 2020-12-30 2025-12-09 キナーゼ阻害剤としてのインダゾール化合物

Country Status (15)

Country Link
US (3) US12264149B2 (https=)
EP (1) EP4271673A1 (https=)
JP (2) JP7791196B2 (https=)
KR (1) KR20230152654A (https=)
AU (1) AU2021411587B2 (https=)
CA (1) CA3205986A1 (https=)
CL (1) CL2023001951A1 (https=)
CO (1) CO2023008689A2 (https=)
CR (1) CR20230325A (https=)
EC (1) ECSP23048136A (https=)
IL (1) IL304014A (https=)
MX (1) MX2023007793A (https=)
PE (1) PE20240687A1 (https=)
WO (1) WO2022147246A1 (https=)
ZA (1) ZA202306559B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CR20230325A (es) 2020-12-30 2023-12-11 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
JP2025525433A (ja) * 2022-06-29 2025-08-05 タイラ・バイオサイエンシーズ・インコーポレイテッド インダゾール化合物
EP4547670A1 (en) * 2022-06-29 2025-05-07 Tyra Biosciences, Inc. Polymorphic compounds and uses thereof
JP2025529161A (ja) 2022-08-30 2025-09-04 タイラ・バイオサイエンシーズ・インコーポレイテッド 活性化fgfr3遺伝子変化を有する固形腫瘍を処置する方法
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024137742A1 (en) 2022-12-20 2024-06-27 Blueprint Medicines Corporation Compounds and compositions as fgfr3 degraders and uses thereof
WO2024138112A1 (en) * 2022-12-22 2024-06-27 Tyra Biosciences, Inc. Indazole compounds
KR20250128350A (ko) * 2022-12-30 2025-08-27 장슈 야홍 메디텍 코퍼레이션 리미티드 피라졸 융합된 고리 화합물, 및 이의 제조 방법 및 용도
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
CN119306723B (zh) * 2023-07-13 2026-04-10 长春金赛药业有限责任公司 吲唑类fgfr2/3选择性抑制剂、药物组合物及其应用
WO2025021033A1 (zh) * 2023-07-21 2025-01-30 长春金赛药业有限责任公司 成纤维细胞生长因子受体抑制剂、药物组合物及其应用
WO2025021997A1 (en) 2023-07-27 2025-01-30 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts New map4k1 inhibitors
WO2025061029A1 (en) * 2023-09-18 2025-03-27 3H Pharmaceuticals Co., Ltd. Fgfr inhibitors and methods of use thereof
TW202519212A (zh) 2023-09-22 2025-05-16 美商泰拉生物科學公司 組合治療療法
WO2025129014A1 (en) * 2023-12-15 2025-06-19 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer
WO2025170959A1 (en) 2024-02-05 2025-08-14 Tyra Biosciences, Inc. Combination of the fgfr 3 inhibitor tyra-300 and a nectin-4 targeting agent-drug conjugate for use in the treatment of cancer
WO2025199217A1 (en) 2024-03-19 2025-09-25 Tyra Biosciences, Inc. Pharmaceutical compositions
WO2026020109A1 (en) * 2024-07-19 2026-01-22 Tyra Biosciences, Inc. Combination treatment comprising a fgfr3 inhibitor and a pd-1/pd-l1 inhibitor for use in the treatment of cancer
WO2026035809A1 (en) * 2024-08-06 2026-02-12 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPS62135835A (ja) 1985-12-09 1987-06-18 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料の処理方法
JPS62135834A (ja) 1985-12-09 1987-06-18 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料の処理方法
JPS62135832A (ja) 1985-12-09 1987-06-18 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料の処理方法
JPS62135830A (ja) 1985-12-09 1987-06-18 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料及びその処理方法
JPS62136651A (ja) 1985-12-10 1987-06-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料の処理方法
JPS62136654A (ja) 1985-12-10 1987-06-19 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JPS62136650A (ja) 1985-12-11 1987-06-19 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料及びその処理方法
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
GB8808433D0 (en) 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5041453A (en) 1990-05-30 1991-08-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
JP2000507955A (ja) 1996-04-03 2000-06-27 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
HUP0004150A3 (en) 1997-11-04 2001-08-28 Pfizer Prod Inc Indazole derivatives as tyrosine kinase receptor antagonists and pharmaceutical compositions containing them
WO1999023076A1 (en) 1997-11-04 1999-05-14 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
EP1046631A1 (en) 1999-04-19 2000-10-25 Rolic AG Liquid crystalline compounds
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
CN1300116C (zh) 2001-04-16 2007-02-14 卫材株式会社 1h-吲唑化合物
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
CA2482838A1 (en) 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compounds and pharmaceutical compositions containing the compound
EP1545515A1 (en) 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
EP1723126A2 (en) 2003-10-22 2006-11-22 Eli Lilly And Company Novel mch receptor antagonists
WO2005060958A1 (en) 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
CN101128441A (zh) 2005-03-04 2008-02-20 默克公司 具有抗糖尿病活性的稠合芳香化合物
WO2007050124A1 (en) 2005-05-19 2007-05-03 Xenon Pharmaceuticals Inc. Fused piperidine derivatives and their uses as therapeutic agents
WO2007044085A2 (en) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
JP5255559B2 (ja) 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
DE102006030479A1 (de) 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
WO2008008650A1 (en) 2006-07-10 2008-01-17 Indiana University Research And Technology Corporation Methods for treating cystic kidney diseases
US20110008347A1 (en) 2006-12-01 2011-01-13 Agency For Science ,Technology And Research Cancer-related protein kinases
CN101687789A (zh) 2007-02-12 2010-03-31 因特蒙公司 C型肝炎病毒复制的新颖抑制剂
EP2074114B1 (en) 2007-04-25 2013-03-06 Exelixis, Inc. Pyrimidinones as casein kinase ii (ck2) modulators
US8338458B2 (en) 2007-05-07 2012-12-25 Merck Sharp & Dohme Corp. Method of treatment using fused aromatic compounds having anti-diabetic activity
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
WO2010065668A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8759337B2 (en) 2008-12-22 2014-06-24 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
EP2368876A1 (en) 2010-03-01 2011-09-28 Sanofi Derivatives of aminoindanes, their preparation and their application in therapeutics
WO2011109551A2 (en) 2010-03-03 2011-09-09 Calcimedica Inc. Compounds that modulate intracellular calcium
JP5763937B2 (ja) 2010-03-10 2015-08-12 Agcセイミケミカル株式会社 液晶化合物、その製造方法、液晶組成物および液晶電気光学素子
MA34300B1 (fr) 2010-05-13 2013-06-01 Amgen Inc Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
BR112013002112B1 (pt) 2010-07-29 2021-04-06 Rigel Pharmaceuticals, Inc. Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
US8883793B2 (en) 2010-12-29 2014-11-11 Development Center For Biotechnology Tubulin inhibitors and methods of using the same
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN103702961A (zh) 2011-05-23 2014-04-02 赛诺菲 含有n-烷基的氘代化合物的制备方法
CN102243505B (zh) 2011-07-07 2013-08-14 矽力杰半导体技术(杭州)有限公司 一种低失调、快速响应的电压控制电流源、控制方法以及应用其的电源电路
EP2740803A4 (en) 2011-08-05 2015-03-25 Astellas Pharma Inc METHOD FOR RECOGNIZING NEW FGFR4 MUTANTS
HK1199259A1 (en) 2011-08-15 2015-06-26 Intermune, Inc. Lysophosphatidic acid receptor antagonists
BR112014004569A2 (pt) 2011-09-01 2017-06-13 F. Hoffmann-La Roche Ag composto da fórmula i, métodos para tratar condição inflamatória, artrite reumatoide, asma e distúrbio imune, composição farmacêutica e uso do composto
EP2753605B1 (en) 2011-09-09 2019-03-27 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
CN103420906B (zh) 2012-05-21 2015-09-09 南京圣和药业股份有限公司 新型酪氨酸蛋白激酶抑制剂
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
CA2890346A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
WO2014113485A1 (en) 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
EP2945652B1 (en) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
KR101648141B1 (ko) 2013-06-11 2016-08-12 제일모직 주식회사 화합물, 이를 포함하는 유기 광전자 소자 및 상기 유기 광전자 소자를 포함하는 표시장치
WO2015008844A1 (ja) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Fgfr阻害剤耐性癌の治療薬
US10323285B2 (en) 2013-09-09 2019-06-18 Nantomics, Llc Proteomics analysis and discovery through DNA and RNA sequencing, systems and methods
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
US9546162B2 (en) 2013-09-27 2017-01-17 Allergan, Inc. Compounds and methods for skin repair
WO2015082499A2 (en) 2013-12-03 2015-06-11 Iomet Pharma Ltd Pharmaceutical compound
CN104946737B (zh) 2013-12-11 2019-02-22 安可济控股有限公司 用于检测罕见序列变体的组合物和方法
US10391081B2 (en) 2013-12-27 2019-08-27 Chugai Seiyaku Kabushiki Kaisha FGFR gatekeeper mutant gene and drug targeting same
WO2015103527A1 (en) 2014-01-06 2015-07-09 The Scripps Research Institute Modulators of rev-erb
US20160340742A1 (en) 2014-02-04 2016-11-24 Mayo Foundation For Medical Education And Research Method of Identifying Tyrosine Kinase Receptor Rearrangements in Patients
SG11201607772WA (en) 2014-03-31 2016-10-28 Debiopharm Int Sa Fgfr fusions
US10351527B2 (en) 2014-04-09 2019-07-16 The University Of British Columbia Binding function 3 (BF3) site compounds as therapeutics and methods for their use
JP6788577B2 (ja) 2014-05-09 2020-11-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 液晶媒体およびそれを含む高周波数素子
ES2842592T3 (es) 2014-05-19 2021-07-14 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
CN107427524A (zh) 2014-08-28 2017-12-01 翁科埃斯克斯有限公司 利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法
US20170369780A1 (en) 2014-11-11 2017-12-28 Merck Patent Gmbh Bimesogenic compounds and mesogenic media
JP2018027019A (ja) 2014-11-26 2018-02-22 国立研究開発法人国立がん研究センター 胆道がんにおける新規治療標的融合遺伝子
WO2016105503A1 (en) 2014-12-24 2016-06-30 Genentech, Inc. Therapeutic, diagnostic and prognostic methods for cancer of the bladder
EP3265462A1 (en) 2015-03-03 2018-01-10 INSERM - Institut National de la Santé et de la Recherche Médicale Fgfr3 antagonists
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
CN106317023A (zh) * 2015-07-10 2017-01-11 中国科学院上海药物研究所 吲唑类化合物的制备方法和用途
EP3333157B1 (en) * 2015-08-07 2020-12-23 Harbin Zhenbao Pharmaceutical Co., Ltd. Vinyl compounds as fgfr and vegfr inhibitors
WO2017066705A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
AU2016341259B2 (en) 2015-10-22 2019-09-12 Selvita S.A. Pyridone derivatives and their use as kinase inhibitors
KR20180118739A (ko) 2016-03-02 2018-10-31 제이엔씨 주식회사 적층체, 전자 기기, 적층체 제조 방법
US20190055444A1 (en) 2016-03-02 2019-02-21 Jnc Corporation Composition for low thermal expansion members, low thermal expansion member, electronic device, and method for producing low thermal expansion member
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
WO2017194665A1 (en) 2016-05-12 2017-11-16 Merck Patent Gmbh Bimesogenic compounds and mesogenic media
KR102605996B1 (ko) 2016-08-30 2023-11-27 다우 글로벌 테크놀로지스 엘엘씨 아크롤레인의 농도의 저감 방법
JP6589795B2 (ja) 2016-09-27 2019-10-16 信越化学工業株式会社 スルホニウム塩、レジスト組成物及びパターン形成方法
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019018795A1 (en) 2017-07-20 2019-01-24 Yumanity Therapeutics COMPOUNDS AND USES THEREOF
WO2019034172A1 (zh) 2017-08-18 2019-02-21 上海轶诺药业有限公司 一种具有pd-l1抑制活性的化合物、其制备方法及用途
US11795162B2 (en) 2017-08-18 2023-10-24 Saint Louis University Modulators of the estrogen-related receptor
WO2019209948A1 (en) 2018-04-25 2019-10-31 Yumanity Therapeutics, Inc. Compounds and uses thereof
EP3847159A2 (en) 2018-09-04 2021-07-14 Magenta Therapeutics, Inc. Aryl hydrocarbon receptor antagonists and methods of use
KR102127006B1 (ko) 2018-12-06 2020-06-25 한국생산기술연구원 피리미딘계 작용기 함유 단분자 화합물, 상기 화합물의 광가교물을 포함한 유기물층 및 이를 포함하는 유기전자소자
CA3124970A1 (en) 2018-12-28 2020-07-02 Cedars-Sinai Medical Center Methods of treating inflammatory bowel diseases that target ripk2
CN111434655A (zh) 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
IN201941011265A (https=) * 2019-03-22 2020-09-25
TW202108582A (zh) 2019-05-14 2021-03-01 大陸商上海翰森生物醫藥科技有限公司 含二並環類衍生物抑制劑、其製備方法和應用
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
WO2021067374A1 (en) * 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為fgfr抑制劑之雙環雜環
CN112812014B (zh) 2019-11-15 2024-05-10 石家庄诚志永华显示材料有限公司 化合物、液晶组合物、液晶显示器
WO2021104305A1 (zh) 2019-11-26 2021-06-03 上海翰森生物医药科技有限公司 含氮多环类衍生物抑制剂、其制备方法和应用
WO2021127333A1 (en) 2019-12-19 2021-06-24 Casma Therapeutics, Inc. Trpml modulators
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
US20230128972A1 (en) 2020-01-31 2023-04-27 Atomwise Inc. Anat Inhibitors and Methods of Use Thereof
WO2021161230A1 (en) 2020-02-12 2021-08-19 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
US20230148214A1 (en) 2020-03-06 2023-05-11 ESCAPE Bio, Inc. Indazoles and azaindazoles as lrrk2 inhibitors
WO2021183970A1 (en) 2020-03-13 2021-09-16 University Of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
CA3182162A1 (en) 2020-05-06 2021-11-11 Les Laboratoires Servier New macrocyclic lrrk2 kinase inhibitors
CR20230325A (es) 2020-12-30 2023-12-11 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
TW202304935A (zh) 2021-03-18 2023-02-01 法商施維雅藥廠 新穎的巨環lrrk2激酶抑制劑
WO2022198112A1 (en) 2021-03-19 2022-09-22 Arvinas Operations, Inc. Indazole based compounds and associated methods of use
US20240316022A1 (en) 2021-06-30 2024-09-26 Tyra Biosciences, Inc. Indazole compounds
CN119183452A (zh) 2022-04-04 2024-12-24 布雷宁疗法公司 Lrrk2抑制剂
EP4547670A1 (en) 2022-06-29 2025-05-07 Tyra Biosciences, Inc. Polymorphic compounds and uses thereof
JP2025525433A (ja) 2022-06-29 2025-08-05 タイラ・バイオサイエンシーズ・インコーポレイテッド インダゾール化合物
JP2025529161A (ja) 2022-08-30 2025-09-04 タイラ・バイオサイエンシーズ・インコーポレイテッド 活性化fgfr3遺伝子変化を有する固形腫瘍を処置する方法

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
JP2024502433A5 (https=)
BR112023012656A2 (https=)
BR112023009656A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023006729A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021015450A8 (https=)
BR102021015247A2 (https=)
BR102021015220A2 (https=)
BR102021013929A2 (https=)
BR102021012571A2 (https=)
BR102021012230A2 (https=)
BR102021012003A2 (https=)
BR102021012107A2 (https=)
BR102021010467A2 (https=)
BR102021009555A2 (https=)
BR102021009475A2 (https=)